FreeStyle Libre 2 Flash Glucose Monitoring System Control Phase Study for Pediatric Patients - BG

Diabetes Mellitus Clinical Trial

Official title:

FreeStyle Libre 2 Flash Glucose Monitoring System Control Phase Study for Pediatric Patients - BG

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04577976
• Other study ID #: ADC-US-PMS-20194
• Status: Terminated
• Start date: September 23, 2020
• Est. completion date: July 14, 2022

Study information

• Verified date: April 2022
• Source: Abbott Diabetes Care
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective, multi-center, non-randomized, single-arm study intended to characterize the safety of self-monitoring of blood glucose (SMBG) when used to manage diabetes in pediatric patients.

Description:

Approximately 400 subjects aged 4-17 years and older with type 1 or type 2 diabetes, who require daily blood glucose monitoring to manage their diabetes will be enrolled in the study. Subjects and/or their caregivers will utilize capillary SMBG for managing diabetes for 6 months. Subjects and/or their caregivers will maintain a diary/log book of Adverse Events experienced during the duration of the study. Assessment of Adverse Events will occur via self reporting at each monthly visit and/or phone call.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 62
• Est. completion date: July 14, 2022
• Est. primary completion date: July 14, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 17 Years

Eligibility

Inclusion Criteria:

• Subject must be 4 - 17 years of age.

• Subject must have a diagnosis of type 1 or type 2 diabetes mellitus for at least 3 months prior to enrollment.

• Subject is currently using SMBG for managing their diabetes.

• Subject and/or caregiver must be able to read and understand English.

• In the investigator's opinion, the subject and/or caregiver must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.

• Subject and/or parent or guardian must be willing and able to provide written signed and dated informed consent and assent when appropriate.

Exclusion Criteria:

• Subject has previously used a continuous glucose monitoring system to manage their diabetes within the last six (6) months.

• Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.

• Subject is known to be pregnant or is attempting to become pregnant at the time of enrollment.

• Subject is on dialysis at the time of enrollment.

• Subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff.

• Subject currently is participating in another clinical trial.

• Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Device:
• SMBG
Subjects and/or their caregivers will utilize capillary SMBG for managing diabetes for 6 months.

Locations

Country	Name	City	State
United States	The DOCS	Las Vegas	Nevada
United States	Florida Institute	Orlando	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Diabetes Care

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of the SMBG devices. The safety of self-monitoring of blood glucose (SMBG) when used to manage diabetes in a pediatric patient population will be characterized: Serious Adverse events	Rate of Serious Adverse events associated with Hypoglycemia and Hyper glycaemia will be determined. (e.g severe hypoglycemic occurrences requiring health care professional (HCP) intervention including EMT assistance, hospital/clinic visit and/or hospitalization and moderate hypoglycemia in which the patient required the assistance of another person [e.g. as a result of confusion, coma, or seizure] during the study.	six months